WHO ICTRP trial
Safety evaluation and effective dose of PD-1 antibody combined with cordycepin…
ChiCTR2300075042 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300075042 |
|---|---|
| Public title | Safety evaluation and effective dose of PD-1 antibody combined with cordycepin in the treatment of advanced non-small cell lung cance |
| Scientific title | Safety evaluation and effective dose of PD-1 antibody combined with cordycepin in the treatment of advanced non-small cell lung cance |
| Primary sponsor | Changzhou First People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | NSCLC |
| Interventions | Experimental group:PD-1 antibody+ Cordycepin treatment |
| Registration date | Aug 23, 2023 |
| Target size | Experimental group:6 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: